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Abstract. 
Strongyloidiasis is an intestinal parasitic infection becoming increasingly important outside endemic areas, not 
only because of the high prevalence found in migrant populations, but also because immunosuppressed patients 
may suffer a potentially fatal disseminated disease. The aim of these guidelines is to provide evidence-based 
guidance for screening and treatment of strongyloidiasis in non-endemic areas. A panel of experts focused on 
three main clinical questions (who should be screened and how, how to treat), and reviewed pertinent literature 
available in international databases of medical literature and in documents released by relevant 
organizations/societies. A consensus of the experts’ opinion was sought when specific issues were not covered 
by evidence. In particular, six systematic reviews were retrieved and constituted the main support for this work. 
The evidence and consensus gathered led to recommendations addressing various aspects of the main questions. 
Grading of evidence and strength of recommendation were attributed to assess the quality of supporting 
evidence. The screening of individuals at risk of the infection should be performed before they develop any 
clinical complication. Moreover, in immunosuppressed patients, the screening should be mandatory. The 
screening is based on a simple and widely accessible technology and there is now a universally accepted 
treatment with a high efficacy rate. Therefore, the screening could be implemented as part of a screening 
program for migrants although further cost-effectiveness studies are required to better evaluate this strategy 
from a public health point of view. 
INTRODUCTION 
Strongyloidiasis is a parasitic disease widely distributed in tropical and subtropical 
regions,1 with over 350 million people estimated to be infected worldwide.2 Migrant 
populations living in European countries present a high risk of having strongyloidiasis,3,4 and 
it has been reported that the prevalence in immigrants may range from 2% to 46%,5 but few 
studies have assessed the burden and risk factors of imported strongyloidiasis.3,6 
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The infection has three peculiar characteristics that are of importance from the clinical 
and public health point of view. First, more than half of infected subjects are asymptomatic or 
have mild, not specific complains,6 and eosinophilia is often the only finding.4 Therefore, 
they are usually unaware that they might harbor an infection.7 Second, Strongyloides 
stercoralis has the ability to replicate indefinitely inside the host (autoinfective cycle) without 
any further exposure to an infected site, thus causing a lifelong infection if left untreated.8,9 
Third, immunosuppressed patients can develop the hyperinfection syndrome or the 
disseminated disease, which has a fatality rate of 60–70%.10 The most frequent trigger of this 
complication is a chronic therapy with steroids, but solid organ or bone marrow transplant 
recipients, patients with malignancies, or those under therapy with immunosuppressive drugs 
are also at risk.11 Human T-cell lymphotropic virus 1 (HTLV-1) is also a risk factor for 
severe disease and treatment failure.12,13 
The rationale for a screening of S. stercoralis in non-endemic countries is based on the 
high estimated prevalence of the infection among migrants, the availability of a sensitive 
method for detection, and the potential to prevent fatal complications through early case 
detection. Currently, a few societies/organizations recommend screening for S. stercoralis in 
specific fields, such as solid organ transplantation,14 since it has been recognized that 
strongyloidiasis can be acquired from an infected donor.15–17 
Different screening strategies include universal screening (when all individuals in a 
certain category are tested)18 and case finding (when only a well-defined group with risk 
factors are candidates for screening).19 
OBJECTIVES 
These guidelines are aimed to provide evidence-based guidance and, when not available, 
consensus opinion from a group of experts to address the screening and treatment of 
strongyloidiasis in non-endemic areas. 
The following definitions were used in these guidelines: 
1. Individuals with high risk of exposure to S. stercoralis: immigrants coming from endemic areas (Africa, Latin 
America, Asia, and Oceania), adopted children who have been living for at least 1 year in highly endemic area, 
expatriates 1) undertaking long trips (more than 1 year) to endemic countries and 2) with exposure to rural areas. 
2. Individuals with intermediate to low risk of exposure to S. stercoralis: short-term (less than 1 year) travelers 
to highly endemic areas; elderly patients living in countries where transmission was occurring in the past, which 
include Northern Italy20 and the Spanish Region of Valencia.21 
3. Immunosuppressed: patients in chronic treatment with corticosteroids, chemotherapy, immunosuppressant 
and immunomodulator agents, transplant recipients, patients with acquired immune deficiency syndrome or 
HTLV-1 infection or any immunosuppression condition. 
4. Candidates for immunosuppression: candidates for immunosuppressant therapies (see above), candidates for 
solid or bone-marrow transplant. Patients with well-controlled human immunodeficiency virus infection should 
be managed like non-immunosuppressed individuals. 
5. Disseminated strongyloidiasis: severe infection with presence of parasites outside the classical life cycle (i.e., 
in organs other than the skin, gastrointestinal tract, lungs). 
6. Strongyloides hyperinfection: increase in the number of larvae in the stools and/or sputum along with clinical 
manifestations limited to the respiratory and gastrointestinal systems, and peritoneum. 
METHODS 
Panel composition. 
We convened a panel of six experts, all of them specialists in migrant health and imported 
diseases, with a particular experience in strongyloidiasis. 
The panel addressed the following three clinical questions: 
1. Who should be screened? 
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2. How to screen strongyloidiasis? 
3. How to treat strongyloidiasis? 
Literature review and analysis. 
Panel members thoroughly reviewed the literature pertinent to each of the question using 
Pubmed/Medline and Cochrane library. 
They particularly evaluated the results of four recent systematic reviews (SRs) about 
strongyloidiasis published by the COHEMI project. All these SRs had been undertaken by 
five members of the panel. The COHEMI project comprehensively reviewed different aspects 
of strongyloidiasis and the final results were four SRs published in peer-reviewed 
journals3,7,10,22 and another study that evaluated the accuracy of five different serological 
assays for the screening, diagnosis, and follow-up of S. stercoralis infection.23,24 
Moreover, other SRs on strongyloidiasis have been additionally included for the 
guidelines development. For this purpose, panel members thoroughly reviewed the literature 
pertinent to each of the question using PubMed/Medline, Embase, CINAHL, Cochrane 
CENTRAL, as well as grey literature for other relevant documents as well as published 
guidelines and reports on screening for strongyloidiasis in relevant organizations (e.g., 
European Centre for Disease Prevention and Control, World Health Organization [WHO]) 
databases. 
Process overview. 
In creating the guidelines, the panel applied the same principles as the Agency for 
Healthcare Research and Quality.25 
This included the available evidence based on the SRs and the grading of the 
recommendations. The panel members reviewed each recommendation, their strengths, and 
the quality of evidence. Discrepancies were discussed and resolved, to achieve a consensus 
for each recommendation. The strength assigned to a recommendation reflects the panel’s 
confidence that the benefits of following the recommendation are likely to outweigh potential 
harms. 
Grading of evidence. 
Ia: SR or meta-analysis of randomized controlled trials (RCTs). 
Ib: at least one RCT. 
IIa: at least one well-designed controlled study without randomization. 
IIb: at least one well-designed quasi-experimental study, such as a cohort study. 
III: well-designed nonexperimental descriptive studies, such as comparative studies, correlation studies, case-
control studies, and case series. 
IV: expert committee reports, opinions, and/or clinical experience of respected authorities. 
Grading of recommendations. 
A: based on hierarchy I evidence. 
B: based on hierarchy II evidence or extrapolated from hierarchy I evidence. 
C: based on hierarchy II evidence or extrapolated from hierarchy I or II evidence. 
D: directly based on hierarchy IV evidence or extrapolated from hierarchy I, II, or III evidence. 
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RESULTS 
Six SRs have been finally included in Table 1. 
Who should be screened? 
First, epidemiological data are important to identify patients at risk of exposure to S. 
stercoralis. However, there is limited evidence in the literature providing prevalence data of 
strongyloidiasis. In one SR about imported strongyloidiasis, prevalence ranged from 0.4 to 
46%, which varied depending on the diagnostic technique used and the targeted population 
(migrant and/or refugees).26 Another SR suggests that S. stercoralis affects between 10% and 
40% of the population in most tropical and subtropical countries5; this study also estimates 
high infection rates in refugees and migrants living in non-endemic areas, reaching 
prevalences up to 75%.5 However, infection rates varied substantially depending on the 
refugees’ country of origin and the studies analyzed suggest that the infection may be 
underreported, especially in sub-Saharan Africa and southeast Asia.5 
Second, we should differentiate between 1) patients with high risk of exposure to S. 
stercoralis and 2) patients with intermediate–low risk of exposure, as defined previously. 
Moreover, the risk of developing a severe disease is not the same in all patients harboring 
the infection. Most infected subjects will never incur in the complicated form throughout 
their life,8 whereas immunocompromised patients are at risk of developing a severe, life-
threatening disease.10 
Therefore, when considering the screening for S. stercoralis, we should differentiate two 
clinical situations. 
Immunocompetent patients. 
The economic benefits of soil-transmitted infections screening in asymptomatic 
immunocompetent individuals, both in cost per hospitalization averted and disability-adjusted 
life years, have been evaluated through cost-effectiveness studies conducted in the United 
States.27,28 
The results of these economic analyses showed that universal screening and presumptive 
antiparasitic treatment were more cost-effective strategies to control soil-transmitted 
helminths in immigrants entering United States, compared with a “watchful waiting” 
strategy.27 However, these studies did not consider serology as a screening method, nor new 
data about the efficacy of ivermectin for the treatment of strongyloidiasis.29 
Testing for S. stercoralis has been suggested only for patients with eosinophilia (> 500 
eosinophils-per-microliter of blood) returning from the tropics.30 Eosinophilia is a frequent 
(48–78%) finding in patients with strongyloidiasis,31–33 but clearly, its absence does not 
exclude the infection.22 It is a too weak predictor of strongyloidiasis in migrants.22,34,35 
Hence, strongyloidiasis should be ruled out in any individual at risk of the infection and 
with eosinophilia as part of the differential diagnosis of eosinophilia. However, a two-step 
screening strategy (blood count and serological test if eosinophilia is present) is not 
recommended considering 1) the need of two accesses of the patient to the laboratory and 2) 
the insufficient sensitivity of eosinophilia. 
Recommendations. 
“Immunocompetent patients who present high risk of exposure to S. stercoralis infection 
should be routinely screened for strongyloidiasis.” 
Page 5 of 18 
Grading of evidence: III 
Grading of recommendations: D 
Immunosuppressed patients/candidates for immunosuppression (see “Definitions”). 
People exposed to immunosuppressant conditions should be particularly targeted due to 
the increased risk of developing severe disease that has a high mortality rate.10,36 A study that 
evaluated the risk factors for developing strongyloidiasis hyperinfection concluded that all 
patients with severe disease were immunocompromised.37 As it has already been mentioned, 
a wide variety of predisposing factors has been described: hematologic malignancies, 
transplantation, immunosuppressant drugs. Steroids remain the most frequent risk factor for 
developing severe disease, which has been reported even during short steroid courses.37,38 It 
is difficult to quantify the risk of developing hyperinfection or disseminated disease in case of 
immunosuppression and also the amount of risk of complication involved in each particular 
type of immunosuppression is unknown. To sum up, immunosuppression poses the patients 
at risk of developing the severe disease; it has been recommended to screen the patients for S. 
stercoralis before administering immunosuppressant therapy, as well as before 
transplantation or other immunosuppressant conditions.10 
Finally, and considering the high efficacy and tolerability of ivermectin, it might be 
probably worth treating high-risk patients preemptively in case an appropriate test (stool 
culture or serology) is not available.10 
Recommendations.  
“Immunosuppressed patients and candidates for immunosuppression should be routinely 
screened for strongyloidiasis if they have high or intermediate risk of exposure to S. 
stercoralis. 
If an appropriate diagnostic test is not available, specific treatment with ivermectin should 
be preemptively provided.” 
Grading of evidence: Ia 
Grading of recommendations: B 
How to screen? 
The diagnosis of S. stercoralis infection is hampered by the low sensitivity of fecal-based 
tests and the suboptimal specificity of most serological test.22 
Direct methods (parasitological-based methods). 
A single stool examination fails to detect S. stercoralis larvae in up to 70% of cases. 
Repeated examinations of stool specimens improve the chances of finding parasites; in some 
studies, diagnostic sensitivity increases to 50% with three stool examinations.39,40 
A recent meta-analysis on the evaluation of conventional parasitological methods found 
the highest sensitivity (89%) for agar plate culture, followed by the Baermann technique 
(72%), FECT (48%), and direct wet smear (21%).41 In most of the diagnostic studies on 
strongyloidiasis, the reference standard used was based on fecal methods.22 However, the 
sensitivity of any fecal-based reference standard may be suboptimal, especially in chronic 
infections where larval output is often very low. 
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Indirect methods (serology). 
Serological methods are the most sensitive available diagnostic tools. There are several 
serologic tests that demonstrated better sensitivity compared with stool methods.42–49 
However, false-negative results occur, especially in acute infections50 and in 
immunosuppressed patients22,33,51,52 and false-positive results can occur because of other 
helminthic infection, especially nematodes.23 
A diagnostic accuracy trial has evaluated five different serological tests for S. stercoralis, 
including the two commercially available Bordier-ELISA (enzyme-linked immunosorbent 
assay) and IVD-ELISA.23 The two latter tests showed a high sensitivity and specificity: 
91.2% and 99.1% for IVD-ELISA, 89.5% and 98.3% for Bordier-ELISA. 
Recommendation.  
“Screening should be performed with a highly sensitive serological test. If not available, 
improved fecal techniques could also be used (Baermann or agar plate culture).” 
Grading of evidence: Ia 
Grading of recommendations: B 
Recommendation.  
“In immunosuppressed patients, a combination of serological and parasitological methods 
(see above) is mandatory, and screening should be performed before the immunosuppression 
if possible, first to avoid the risk of severe disease and second because serology is less 
sensitive once immunosuppression has already been established.” 
Grading of evidence: III 
Grading of recommendations: D 
COHEMI recommendations for screening are resumed in Figure 1. 
How to treat? 
A recent Cochrane SR has reported a higher cure rate of strongyloidiasis with ivermectin 
compared with albendazole and a better tolerance. Similar cure rates were observed when 
ivermectin was compared with thiabendazole but more adverse events were reported with the 
second drug.53 
Most trials were relatively small, with less than 100 patients per arm. All trials but one 
exclusively relied on fecal diagnostic methods for the assessment of cure. 
The main findings of the trials are summarized in Table 2 (that includes also trials not 
considered in the Cochrane review). The number needed to treat was also calculated for each 
trial. 
Albendazole versus placebo. 
A double-blind, placebo-controlled trial evaluated the efficacy of albendazole for several 
intestinal helminths, including S. stercoralis at the dose of 400 mg daily for 3 consecutive 
days, and showing a cure rate of 48%.54 
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Albendazole at high dosage. 
An RCT comparing two different, high dosage schedules of albendazole showed an 
efficacy of 87.9% for albendazole (800 mg twice daily for 3 days) and 89.5% for albendazole 
(800 mg twice daily for 5 days) with no significant difference.55 
Albendazole versus ivermectin. 
Six RCTs were carried out from 1994 to 2011, on ivermectin single standard dose for 1 or 
2 days, versus albendazole at different dose schedules, including high dosage. All invariably 
showed a superiority of ivermectin, with cure rates ranging from 83% to 100% for the latter, 
and from 38% to 79% for albendazole.56–60 
Albendazole versus thiabendazole. 
We retrieved a single RCT61 reporting a similar high cure rate for albendazole at high 
dose (800 mg daily for 5 consecutive days, with cure rate 95%) and thiabendazole (1 g twice 
daily for 5 days, with cure rate 100%). The sample size of this study was particularly small, 
with 35 patients enrolled overall and a short duration of follow-up (21 days). 
Thiabendazole versus ivermectin. 
Three RCTs compared the two drugs,62–64 all demonstrating equivalent efficacy and a 
much higher incidence of untoward effects for thiabendazole. 
Recommendations.  
“Chronic (uncomplicated) strongyloidiasis should be treated with ivermectin.” 
Grading of evidence: Ia 
Grading of recommendations: A 
At the moment, the recommended dosage is a stat dose of 200 µg/kg (as reported in the 
patient information leaflet), although some authors suggest that multiple doses might increase 
the efficacy.65 The WHO model drug formulary66 gives both options: 1 day versus 2 
consecutive days, single dose. Two trials compared the two different regimens of ivermectin, 
the first one published in 199462 and with small numbers reported a cure rate of 100% with 
both schemes, whereas the second and more recent one60 reported a slightly higher cure rate 
(not statistically significant) for the single dose (97% versus 93%). A multicenter RCT is 
currently underway (including serology for assessment of cure), comparing single to multiple 
doses of ivermectin.67 
Empiric treatment. 
In case adequate laboratory facilities are not available, and the infection cannot be 
excluded, empiric treatment might be worth, in consideration of the good tolerability of the 
drug and the potential harm caused by a missed diagnosis.65 This is particularly advised for 
patients who are candidate to be immunosuppressed, such as, but not limited to, transplant 
recipients.68 
Recommendation.  
“Empiric treatment of patients at risk of immunosuppression, if past exposure cannot be 
excluded, is indicated without testing in case of lack of adequate diagnostic facilities (see the 
section ‘How to screen?’).” 
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Grading of evidence: IV 
Grading of recommendations: D 
Follow-up after treatment. 
Evidence summary. 
A posttreatment evaluation with parasitological methods does not reliably exclude the 
infection, as the sensitivity of these methods is low. Several studies have reported that the 
serologic titer usually tends to decrease after treatment,48,64,69–71 but uniform criteria to define 
cure have not been established.22,42 Recently, it has been shown that, for all of the five tests 
analyzed by a diagnostic study (three ELISA tests, one LIPS, and one IFAT), the 
OD/luminescence/titer consistently showed a diminishing trend with time, tending to 
negativization, for the cases treated successfully, although the time required may be as long 
as 12 months or more.24 Failure to achieve a significant reduction in titer or OD (to 50% or 
less of the OD prior to treatment, or at least two IFAT dilutions) should be considered as a 
potential treatment failure, even if fecal-based tests are negative. 
Recommendations.  
“Posttreatment follow-up should be performed with the most sensitive technique 
available. Serology should be done at baseline and repeated after 6 and 12 months after 
treatment to monitor the decrease in OD/titer or negativization.” 
Grading of evidence: IIb 
Grading of evidence: C 
DISCUSSION 
There are several reasons that justify the screening in asymptomatic people. 
In the first place, an early detection of the infection in individuals at risk, before they 
develop any clinical complication, is in itself a sufficient argument to propose a screening. 
Moreover, in immunosuppressed patients, the screening should be mandatory. Second, there 
is a drug, ivermectin, which is now the universally accepted treatment with a high efficacy 
rate and a low rate of adverse effects. Third, the screening is based on a simple and widely 
accessible technology, including commercially available tests that are highly sensitive. The 
screening could be implemented as part of a screening program for migrants, although further 
cost-effectiveness studies are required to better evaluate this strategy from a public health 
point of view. 
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FIGURE 1. Algorithm diagnosis of screening. * When serology or more sensitive stool techniques (Baermann or 
stool culture) are not available, consider empiric treatment with ivermectin. This figure appears in color at 
www.ajtmh.org. 
TABLE 1 
Systematic reviews finally included 
Title Author Year Topic on 
Strongyloides 
Reference 
Imported strongyloidiasis: epidemiology, 
presentations, and treatment 
Buonfrate 
and others 
2012 Prevalence 26 
Prevalence of strongyloidiasis in Latin America: 
a systematic review of the literature 
Buonfrate 
and others 
2015 Prevalence 7 
Strongyloides stercoralis: global distribution 
and risk factors. 
Schär and 
others 
2013 Prevalence 5 
The laboratory diagnosis and follow-up of 




2013 Diagnosis 22 







Ivermectin vs. albendazole or thiabendazole for 




2016 Treatment 53 
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TABLE 2 
Summary of published trials of strongyloidiasis treatment 
Author Drug(s), dose Diagnostic methods Cured (%) NTT P 
value 
Reference 
Placebo 0/31 (0) Pene and others 
Albendazole 400 mg/day × 3 days 
Harada-Mori 
12/25 (48) 
2.08 NS 54 
Albendazole 800 mg bid for 3 days repeated after 1 week 51/57 (87.9) Singthong and 
others Albendazole 800 mg bid for 5 days repeated after 1 week 
Agar plate culture 
(APC) 51/58 (89.5) 
64.8 NS 55 
Albendazole 400 mg/day × 3 days 9/24 (38) Datry and others 
Ivermectin 150–200 µg/kg single dose 
Fecal smear, Kato, 
FECT/Baermann 24/29 (83) 
2.2 < 0.01 56 
Albendazole 400 mg/day × 3 days 67/149 (45) Marti and others 
Ivermectin 200 µg/kg single dose 
Baermann 
method/Kato-Katz 126/152 (83) 
2.6 < 0.01 57 
Albendazole 800 mg bid for 3 days 65/84 (77.4) 1.35 (iv 
vs. pyr) 
Ivermectin 6 mg single dose 65/67 (97.0) 5.1 (iv 
vs. alb) 
Toma and others 
Pyrvinium pamoate 5 mg/kg for 3 days 
Harada-Mori APC 
14/60 (23.3) – 
< 0.01 58 
Albendazole 400 mg bid for 5 days 26/33 (78.8) Nontasut and 
others Ivermectin 200 µg/kg single dose 
Kato-Katz culture, APC 
77/78 (98.7) 
5 < 0.01 59 
Albendazole 800 mg/day × 7 days 8/21 (38.1) Suputtamongkol 
Ivermectin 200 µg/kg single dose 
FECT 
16/21 (76.2) 
2.625 0.029 73 
Ivermectin 200 µg/kg single dose 30/31 (96.8) 3 
Ivermectin 200 µg/kg single dose for 2 days 27/29 (93.1) 3.6 
Suputtamongkol 
and others 
Albendazole 800 mg/day × 7 days 
Fecal smear, FECT, 
APC 




Albendazole 400 mg bid for 5 days 22/23 (95)  
Thiabendazole 1 g bid for 5 days 
Fecal smear, Harada-
Mori, larva count (Stool 
and Sasa method) 
12/12 (100) 
23   
Ivermectin 200 µg/kg single dose 16/16 (100) 19 
Ivermectin 200 µg/kg single dose for 2 days 18/18 (100) 19 
Gann and others 
Thiabendazole 25 mg/kg bid for 3 days 
Baermann 
18/19 (94.7) – 
NS 62 
Ivermectin 200 µg/kg single dose 95/113 (84.1) 18.4 Adenusi and others 
Thiabendazole 25 mg/kg bid for 3 days 
Baermann 
81/103 (78.6)  
NS 63 
Ivermectin 200 µg/kg single dose 32/47 (68.1)  Bisoffi and others 
Thiabendazole 25 mg/kg bid for 3 days 
APC, serology (IFAT) 
31/45 (68.9) 124.411 
NS 29 
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